Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Assembly Biosciences (ASMB) EBITDA: 2009-2024

Historic EBITDA for Assembly Biosciences (ASMB) over the last 14 years, with Dec 2024 value amounting to -$40.3 million.

  • Assembly Biosciences' EBITDA rose 4.95% to -$9.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$38.5 million, marking a year-over-year increase of 5.42%. This contributed to the annual value of -$40.3 million for FY2024, which is 33.38% up from last year.
  • According to the latest figures from FY2024, Assembly Biosciences' EBITDA is -$40.3 million, which was up 33.38% from -$60.5 million recorded in FY2023.
  • Over the past 5 years, Assembly Biosciences' EBITDA peaked at -$40.3 million during FY2024, and registered a low of -$130.0 million during FY2021.
  • Over the past 3 years, Assembly Biosciences' median EBITDA value was -$60.5 million (recorded in 2023), while the average stood at -$64.8 million.
  • Its EBITDA has fluctuated over the past 5 years, first skyrocketed by 36.18% in 2020, then slumped by 108.94% in 2021.
  • Over the past 5 years, Assembly Biosciences' EBITDA (Yearly) stood at -$62.2 million in 2020, then plummeted by 108.94% to -$130.0 million in 2021, then grew by 28.10% to -$93.5 million in 2022, then surged by 35.27% to -$60.5 million in 2023, then spiked by 33.38% to -$40.3 million in 2024.